Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2017.661 | PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS HARBORING FGF/FGFR ABERRATIONS |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.172 | A phase Ib/II, open-label, multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2016.730 | A study on thromboembolism in pancreatic cancer patients |
Dr. CHAN Stephen Lam 陳林 |
| 2016.016 | A phase III, Open-label, Randomized Study of the Combination Therapy with NC-6004 and Gemcitabine versus Gemcitabine Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer |
Dr. CHAN Stephen Lam 陳林 |
| 2014.535 | A phase I/II, multicenter, open-label study of oral FGF401 in adult patients with hepatocellular carcinoma or solid malignancies characterized by positive FGFR4 and KLB expression | Prof. CHAN Stephen Lam |
| 2022.403 | A Phase 1/ 2a, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma |
Prof. CHAN Stephen Lam 陳林 |
| 2023.513 | A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE) | Prof. CHAN Stephen Lam |
| 2021.428 | Survival analysis for prognostic factors in biliary tract cancer |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2022.463 | A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene |
Prof. CHAN Stephen Lam 陳林 |
| 2022.216 | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106) |
Prof. CHAN Stephen Lam 陳林 |
| 2021.605 | ORGAN-SPECIFIC RESPONSES TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A MULTINATIONAL MULTICENTER STUDY |
Prof. CHAN Stephen Lam 陳林教授 |
| 2022.007 | Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors in hepatocellular carcinoma: A proof-of-concept clinical trial |
Prof. CHAN Stephen Lam 陳林 |
| 2024.003 | A retrospective study on the outcome of patients with pancreatic neuroendocrine tumour in a regional setting | Prof. CHAN Stephen Lam |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephen Lam |
| 2023.345 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Prof. CHAN Stephen Lam 陳林 |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2023.103 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 1: Hepatocellular Carcinoma (HCC) | Prof. CHAN Stephen Lam |
| 2023.104 | A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA) | Prof. CHAN Stephen Lam |
| 2021.629 | RETROSPECTIVE NON-INTERVENTIONAL STUDY OF THE EFFECTIVENESS AND SAFETY OF LANREOTIDE AUTOGEL® AT A DOSE OF 120 MG ONCE EVERY 28 DAYS IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS (GEP-NETS) IN HONG KONG AND TAIWAN |
Prof. CHAN Stephen Lam 陳林教授 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
| 2023.567 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | Prof. CHAN Stephen Lam |
| 2023.423 | A Clinical Study of Consistency Evaluation on Patient-Derived Organoid in Predicting Treatment Response for Hepatobiliary and Pancreatic Cancer | Prof. CHAN Stephen Lam |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2022.175 | Sequential TransArterial chemoembolization and stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for downstaging hepatocellular carcinoma for hepatectomy |
Prof. CHAN Stephen Lam 陳林醫生 |
| 2024.098 | Establishment of a Hepatocellular Carcinoma Database | Prof. CHAN Stephen Lam |
| 2013.020 | Development of staging system based on circulating inflammatory marker for HCC | Dr. Chan Stephen Lam |
| 2013.019 | Determination of association between serum folate level and toxicity of capecitabine in patients with colorectal cancers: A prospective cohort study | Dr. CHAN Stephen Lam |
| 2011.170 | Psychiatric morbidity in Chinese patients with hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2012.404 | A study to evaluate the impact of liver stiffness on treatment outcome of hepatocellular carcinoma | Dr. CHAN Stephen Lam |
| 2011.332 | A Phase 1b, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of EZN-2968, a Hypoxia-Inducible Factor-1 alpha (HIF-1 alpha) mRNA Antagonist, Administered as a Weekly 2-Hour Intravenous Infusion (for 3 Weeks Per 4-Week Cycle) in Adul | Dr. CHAN Stephen Lam |
| 2011.369 | Validation of prognostic markers in advanced hepatocellular carcinoma and identification of potential serological prognostic markers | Dr. CHAN Stephen Lam |
| 2008.463 | The use of serum hepatitis B viral DNA in prognosticiation of liver cancers undergoing non-surgical therapy | Dr. Chan Stephen Lam |
| 2019.458 | A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma |
Dr. CHAN Stephen Lam 陳林 |
| 2019.096 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.454 | A Randomized, Open-Label, International, Multi-Center, Phase 3 Clinical Study of PD-1 Antibody SHR-1210 Plus Apatinib (Rivoceranib) Mesylate Versus Sorafenib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Therapy |
Dr. CHAN Stephen Lam 陳林 |
| 2019.474 | A PHASE III, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) PLUS BEVACIZUMAB VERSUS ACTIVE SURVEILLANCE AS ADJUVANT THERAPY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA AT HIGH RISK OF RECURRENCE AFTER SURGICAL RESECTION OR ABLATION |
Prof. CHAN Stephen Lam 陳林 醫生 |
| 2019.431 | A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectable Biliary Tract Carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.694 | A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to checkpoint inhibitors |
Dr. CHAN Stephen Lam 陳林 |
| 2019.416 | A Phase III Randomized, Double-Blind, Placebo-Controlled, Multi-Regional, International Study of Durvalumab in Combination with Gemcitabine plus Cisplatin versus Placebo in Combination with Gemcitabine plus Cisplatin for Patients with First-Line Advanced Biliary Tract Cancers (TOPAZ-1) | Dr. CHAN Stephen Lam |
| 2019.651 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2) |
Dr. CHAN Stephen Lam 陳林 |
| 2019.219 | Study on the clinical role of the Albumin-Bilirubin-index (ALBI) in patients treated with lenvatinib or atezolizumab/bevacizumab for hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2020.568 | FOENIX-CCA3: A Phase 3, Open-Label, Randomized Study of Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients with Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements |
Dr. CHAN Stephen Lam 陳林 |
| 2019.259 | Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-1) |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.555 | A Phase Ia/Ib, Open-Label, Dose-Escalation and Dose-Expansion Study of the Anti-CTLA-4 Monoclonal Antibody CS1002 as Monotherapy and in Combination with Anti-PD-1 Monoclonal Antibody CS1003 in Subjects with Advanced Solid Tumors |
Dr. CHAN Stephen Lam 陳林 |
| 2019.636 | Targeting and monitoring MDSCs to improve outcomes of radiofrequency ablation in hepatocellular carcinoma |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2019.387 | A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination with Brivanib Alaninate (ZL-2301) in Patients with Advanced Liver Cancer | Dr. CHAN Stephen Lam |
| 2020.625 | A PHASE II, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB WITH OR WITHOUT BEVACIZUMAB IN COMBINATION WITH CISPLATIN PLUS GEMCITABINE IN PATIENTS WITH UNTREATED, ADVANCED BILIARY TRACT CANCER |
Dr. CHAN Stephen Lam 陳林 醫生 |
| 2011.524 | A study on the ambulatory management of febrile neutropenia in patients with cancer undergoing cytotoxic chemotherapy | Dr. Chan Stephen Lam |
| 2011.030 | A multicenter, global, randomized, double-blind study of axitinib plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy | Prof. CHAN Stephen Lam |
| 2013.001 | A Phase II, open label, single arm, multicenter study of INC280 administered orally in adult patients with advanced hepatocellular carcinoma | Prof. CHAN Stephen Lam |
Page 67 of 262.